Who
Sue Gail Eckhardt
Director
Company insider
Files Form 4 as: Director, Exelixis; Director, Syros Pharmaceuticals.
In numbers
- Trades disclosed
- 25
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $2.5M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 8 Sep 2020
- Last trade
- 1 Jun 2026
- Last filed
- 3 Jun 2026
Companies traded
Activity over time
1 Feb 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jun 2026filed 3 Jun 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $492K9,812 at $50.14 | filing |
| 1 Jun 2026filed 3 Jun 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $492K9,812 at $50.14 | filing |
| 27 May 2026filed 29 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —8,367 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —8,367 at $0.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $169K3,856 at $43.79 | filing |
| 13 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $169K3,856 at $43.79 | filing |
| 2 Jun 2025filed 4 Jun 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $805K18,834 at $42.74 | filing |
| 2 Jun 2025filed 4 Jun 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $1754 at $43.67 | filing |
| 29 May 2025filed 30 May 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —9,812 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,712 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $179K7,712 at $23.24 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $270K7,712 at $35.01 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $135K3,856 at $35.04 | filing |
| 5 Jun 2024filed 7 Jun 2024 | Syros Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | Syros Pharmaceuticals | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 31 May 2024filed 4 Jun 2024 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —18,838 at $0.00 | filing |
| 5 Jan 2024filed 9 Jan 2024 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,848 at $0.00 | filing |
| 5 Jan 2024filed 9 Jan 2024 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —15,424 at $0.00 | filing |
| 1 Jun 2023filed 2 Jun 2023 | Syros Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 1 Jun 2023filed 2 Jun 2023 | Syros Pharmaceuticals | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
News
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmEXEL · prnewswire.com · 13 Oct 2026Exelixis v. MSN Shows the Reach of Earlier Genus PatentsEXEL · natlawreview.com · 7 Oct 2026
0 headlines in the last 90 days name Sue Gail Eckhardt; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.